SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)

Disseminated on behalf of SureNano Science Ltd., may include paid advertisements.

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is a Canadian life sciences company positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. Blockbuster drugs such as Ozempic®, Wegovy®, and Mounjaro® have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments.

Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic. Through its acquisition of GlucaPharm Inc., the company holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University, and is progressing the asset through the U.S. Food and Drug Administration (FDA) pathway with the goal of advancing it into clinical development.

The company’s strategy centers on combining therapeutic innovation with its foundational expertise in formulation and drug delivery to improve tolerability, administration, and patient experience. By focusing on a targeted development pathway within a rapidly expanding market dominated by large incumbents, SureNano aims to position its lead asset as a potential candidate for future partnership or acquisition as it progresses through clinical milestones.

The company is headquartered in Vancouver, British Columbia.

Portfolio

SureNano’s operations are now centered on the development of its lead therapeutic candidate, GEP-44, through its wholly owned subsidiary, GlucaPharm Inc. This asset represents the company’s primary focus as it advances its transition into a pharmaceutical development platform targeting metabolic disease.

GEP-44 is a novel, patented, monomeric peptide developed at Syracuse University that functions as a triple agonist targeting GLP-1 and peptide YY (PYY) receptors Y1 and Y2, which has demonstrated significant weight reduction and blood glucose normalization in preclinical studies, without the nausea and gastrointestinal side effects commonly associated with first-generation GLP-1 drugs currently on the market. This mechanism is designed to integrate glucose regulation, appetite suppression, and improved tolerability within a single molecule, addressing limitations commonly associated with first-generation GLP-1 therapies. GEP-44 is exclusively licensed from Syracuse University and represents a second-generation GLP opportunity targeting comparable or superior efficacy with improved patient tolerability.

In preclinical studies, GEP-44 demonstrated approximately 15% weight loss compared to 9% for liraglutide, along with a 39% reduction in food intake versus 20% for the comparator, while also improving glucose control and showing no observed gastrointestinal side effects such as nausea and vomiting.

The asset is being advanced through IND-enabling studies in collaboration with a contract research organization, with planned progression into clinical trials. SureNano’s foundational expertise in nanotechnology and formulation science, including its SureNano™ emulsifier platform, supports the development of potential non-injectable delivery formats such as oral, nasal, or sublingual administration.

The IND-enabling Good Laboratory Practice toxicology and pharmacology study program for GEP-44 is vital to de-risk the company’s lead candidate and is designed to support its strategy of launching a Phase I clinical trial in Australia, which is expected to be in collaboration with a premier global contract research organization (CRO), LabCorp, known for its expertise in preclinical development (subject to entering into definitive collaboration agreements). The pivotal, GLP-compliant package is specifically designed to assess safety, toxicology, and pharmacology across multiple species, including rodents and non-rodent primates, to evaluate the safety and feasibility of the approach for human clinical application. The studies will provide comprehensive data to determine the maximum tolerated dose (MTD), identify potential biomarkers for monitoring toxicity, assess the reversibility of toxic effects, and establish the safety margin needed for first-in-human studies.

Market Opportunity

SureNano is targeting the global market for metabolic disease therapeutics, which continues to expand due to rising rates of obesity and Type II diabetes. Company materials indicate that the GLP-1 therapeutic market was valued at approximately $24 billion in 2026 and is projected to reach approximately $33 billion by 2030.

The broader obesity treatment market, which includes all therapeutic approaches, was valued at approximately $15.9 billion in 2024 and is forecast to exceed $60 billion by 2030. These trends are supported by global prevalence estimates suggesting that approximately one billion people could be obese by 2030, reinforcing sustained demand for effective pharmacological interventions.

Within this landscape, GLP-based therapies are experiencing strong growth, with long-term projections indicating a multi-hundred-billion-dollar market opportunity over the coming decade. SureNano’s strategy is to position GEP-44 as a next-generation alternative within this category, with a focus on improved tolerability and delivery to expand patient adoption. SureNano’s platform is focused on advancing a differentiated GLP-1 asset with the potential for non-injectable administration, including oral, sublingual, or nasal delivery, which management believes could materially expand patient adoption and long-term market penetration.

As GEP-44 advances through IND, Phase I, and Phase II-III development towards FDA approval, management expects SureNano to be positioned as one of the only micro-cap public companies developing GLP-1 technology, with direct exposure to the multi-hundred-billion-dollar GLP-1 metabolic market, and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.

Leadership Team

Charles MaLette, Chief Executive Officer, President and Director, has more than 35 years of experience as an investment advisor with Canaccord Genuity Corp., where he focused on financing, analyzing, and advising public companies across multiple industries, and holds a degree in economics from the University of Calgary along with a teaching degree from the University of British Columbia.

James Bordian, Chief Financial Officer and Director, is a retired Chartered Accountant and Certified Internal Auditor with over 40 years of experience, including senior management roles at organizations such as Air Canada and BC Hydro, with expertise in financial reporting, tax planning, and business valuation.

Dr. Nihar Pandey, Chief Scientific Officer, is a biochemist and clinical researcher with more than 25 years of experience in drug discovery and development, having developed multiple IP-protected formulations, published extensively in peer-reviewed journals, and held roles at institutions including the University of Ottawa Heart Institute, Liponex Inc., and Health Canada.

Dr. Robert Doyle, Inventor and Advisor, is a medicinal chemist focused on drug development for obesity and type 2 diabetes, with specialization in peptide and protein design, recombinant expression, bioconjugate chemistry, and drug delivery. He joined Syracuse University in 2005, was named the Laura J. and L. Douglas Meredith Professor in 2016 and Dean’s Professor of Chemistry in 2022, and also holds an appointment as Associate Professor of Medicine at SUNY.

Dr. Peter Billing, Obesity Expert and Advisor, is a Mayo-trained metabolic bariatric surgeon, entrepreneur, and clinical investigator who serves as a courtesy medical staff member at Swedish First Hill and holds leadership roles including Medical Director at Transform SurgiCenter. He has a robust publication record on surgical treatments and bariatric procedures and was named a Top Doctor by Castle Connolly in 2023.